A Phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma

Papers of special note have been highlighted as: • of interest; •• of considerable interest.

References

• 1 Wilhelm SM, Carter C, Tang L et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64(19), 7099–7109 (2004).
  Medline CASGoogle Scholar
• 2 Escudier B, Szczylik C, Hutson TE et al. Randomized Phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27(8), 1280–1289 (2009). •• Results from this randomized clinical trial demonstrated the benefit of a dosage escalation strategy after failure at routine dosages.
  Medline CASGoogle Scholar
• 3 Amato RJ, Harris P, Dalton M et al. A Phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (mRCC). J. Clin. Oncol. 25(Suppl. 18), Abstract 5026 (2007). •• This study used a different escalation strategy and observed a promising complete and partial response rate and prolonged progression-free survival in specific patients.
  Google Scholar
• 4 Strumberg, D, Clark JW, Awada A et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four Phase I trials in patients with advanced refractory solid tumors. Oncologist 12(4), 426–437 (2007).
  Medline CASGoogle Scholar
• 5 Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125–134 (2007). • A landmark Phase III trial of sorafenib in patients with renal cell carcinoma (RCC).
  Medline CASGoogle Scholar
• 6 Naito S, Tsukamoto T, Murai M, Fukino K, Akaza H. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a Phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma. BJU Int. 108(11), 1813–1819 (2011).• A Phase II clinical trial from Japan indicating good tolerability and prolonged survival of Asian patients with metastatic RCC.
  Medline CASGoogle Scholar
• 7 Zhang H, Dong B, Lu JJ et al. Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study. BMC Cancer 9, 249 (2009).
  MedlineGoogle Scholar
• 8 Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92(3), 205–216 (2000).
  Medline CASGoogle Scholar
• 9 Orrell DH. Albumin as an aid to the interpretation of serum calcium. Clin. Chim. Acta 35(2), 483–489 (1971).
  Medline CASGoogle Scholar
• 10 Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115–124 (2007).
  Medline CASGoogle Scholar
• 11 Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet 370(9605), 2103–2111 (2007).
  MedlineGoogle Scholar
• 12 Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. 28(6), 1061–1068 (2010).
  Medline CASGoogle Scholar
• 13 Chang YS, Adnane J, Trail PA et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother. Pharmacol. 59(5), 561–574 (2007).
  Medline CASGoogle Scholar
• 14 Mancuso A, Di Paola ED, Leone A et al. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment. BJU Int. 109(2), 200–206 (2012).
  Medline CASGoogle Scholar
• 15 Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 22(3), 454–463 (2004).
  MedlineGoogle Scholar
• 16 Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 27(34), 5794–5799 (2009). •• This study identified some possible prognostic factors for treatment outcome in patients with metastatic RCC treated with targeted therapy agents.
  Medline CASGoogle Scholar
• 17 Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J. Urol. 184(3), 873–878 (2010).
  MedlineGoogle Scholar
• 18 Ohno Y, Nakashima J, Ohori M, Gondo T, Hatano T, Tachibana M. Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. J. Urol. 187(2), 411–417 (2012).
  MedlineGoogle Scholar
• 19 Zahorec R. Ratio of neutrophil to lymphocyte counts – rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl. Lek. Listy 102(1), 5–14 (2001).
  Medline CASGoogle Scholar
• 20 Gore ME, Szczylik C, Porta C et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 10(8), 757–763 (2009).
  Medline CASGoogle Scholar
• 21 Bono P, Rautiola J, Utriainen T, Joensuu H. Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta Oncol. 50(4), 569–573 (2011).
  Medline CASGoogle Scholar
• 22 Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271–2281 (2007).
  Medline CASGoogle Scholar
• 23 Tanigawa G, Kawashima A, Yamaguchi S et al. Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice. Jpn J. Clin. Oncol. 41(11), 1265–1270 (2011).
  MedlineGoogle Scholar
• 24 Ueda T, Imamura Y, Komaru A et al. Treatment outcomes of sorafenib for first line or cytokine refractory advanced renal cell carcinoma in Japanese patients. Int. J. Urol. 17(9), 811–815 (2010).
  Medline CASGoogle Scholar
• 25 Yang L, Shi L, Fu Q et al. Efficacy and safety of sorafenib in advanced renal cell carcinoma patients: results from a long-term study. Oncol. Lett. 3(4), 935–939 (2012).
  Medline CASGoogle Scholar
• 26 Park SJ, Lee JL, Park I et al. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma. Chemotherapy 58(6), 468–474 (2012).
  Medline CASGoogle Scholar
• 27 Zama IN, Hutson TE, Elson P et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 116(23), 5400–5406 (2010).
  Medline CASGoogle Scholar
• 28 Rini BI, Melichar B, Ueda T et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind Phase 2 trial. Lancet Oncol. 14(12), 1233–1242 (2013).
  Medline CASGoogle Scholar